Onxeo
ALONX | PA
Overview
Corporate Details
- ISIN(s):
- FR0010095596 (+3 more)
- LEI:
- 96950018AS30IUG0V528
- Country:
- France
- Address:
- 49 BOULEVARD DU GENERAL MARTIAL VALIN, 75015 PARIS
- Website:
- https://www.onxeo.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Valerio Therapeutics, formerly known as Onxeo until June 2023, is a biotechnology company developing precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which utilizes two fully synthetic single-domain antibody (sdAb) libraries. This ultra-small sdAb platform is engineered for deep tissue penetration and highly precise therapeutic delivery, aiming to surpass the limitations of current treatments. Valerio's integrated approach combines predictive modeling for target identification, antibody engineering, and drug conjugate development. The company's strategy is to advance its therapeutic candidates to clinical proof-of-concept before forming strategic partnerships through co-development, out-licensing, and R&D collaborations to maximize the potential of its innovations.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Onxeo.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-06 17:06 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 245.0 KB | |
| 2025-05-06 17:06 |
Report Publication Announcement
Informations privilégiées / Autres communiqués
|
French | 247.1 KB | |
| 2025-03-19 15:27 |
Board/Management Information
Inside Information / Other news releases
|
English | 146.6 KB | |
| 2025-03-19 12:30 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 192.3 KB | |
| 2025-03-19 12:30 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 257.6 KB | |
| 2025-03-03 17:35 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 274.6 KB | |
| 2025-03-03 17:35 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 207.6 KB | |
| 2024-11-15 08:00 |
Board/Management Information
Inside Information / Other news releases
|
English | 132.0 KB | |
| 2024-11-15 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 194.5 KB | |
| 2024-09-30 22:40 |
Interim Report
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
|
French | 1.7 MB | |
| 2024-09-30 22:40 |
Interim Report
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
|
English | 2.1 MB | |
| 2024-09-30 22:40 |
Earnings Release
Inside Information: News release on accounts, results
|
English | 387.9 KB | |
| 2024-09-30 22:40 |
Interim Report
Inside Information: News release on accounts, results
|
French | 373.1 KB | |
| 2024-09-30 07:00 |
M&A Activity
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 213.4 KB | |
| 2024-09-30 07:00 |
M&A Activity
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 276.8 KB |
Automate Your Workflow. Get a real-time feed of all Onxeo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Onxeo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-09 | N/A | Other | Other | 17,857,143 | 5,000,000.04 EUR |
| 2023-06-09 | N/A | Other | Other | 7,142,857 | 1,999,999.96 EUR |
